Company
Asgard Therapeutics
Reprogramming is the next leap forward in cancer immunotherapy
- Legal name
- Asgard Therapeutics AB
Claim, correct or request removal
Record updated 28 September 2026
About
Asgard Therapeutics is a Swedish private biotech company exploring direct cell reprogramming technologies to develop ground-breaking cancer immunotherapies. Incorporated as a spin-off from Lund University, Asgard is pioneering gene therapy approaches with the proprietary lead program AT-108, designed to set in motion immune responses mediated by the biological properties of professional antigen presenting cells.
Products
- Web
- AT-108
Loading relationship preview